Latest Breaking News On - Severely active crohn - Page 1 : comparemela.com

GALAXI 1 & 2: Guselkumab Superior to Ustekinumab for Crohn's Disease

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

GALAXI 2 & 3: Guselkumab Superior to Ustekinumab for Crohn's Disease

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

Guselkumab for the Treatment of Crohn Disease, with Remo Panaccione, MD

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.